Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hydralazine-induced hepatitis

S Itoh, A Ichinoe, Y Tsukada

    Hepato-Gastroenterology
    |February 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Hydralazine medication can cause liver injury, with symptoms appearing months to years after starting treatment. Discontinuing the drug leads to recovery, suggesting a link between drug metabolism and liver damage.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer.

    Oncogene·2016
    Same author

    Interferon-induced coronary vasospasm. A case history.

    Angiology·1995
    Same author

    cDNA cloning of mouse ferredoxin reductase from kidney.

    Biochimica et biophysica acta·1995
    Same author

    Stabilization of a semiquinone radical at the high-affinity quinone-binding site (QH) of the Escherichia coli bo-type ubiquinol oxidase.

    FEBS letters·1995
    Same author

    Molecular cloning of 25-hydroxyvitamin D-3 24-hydroxylase (Cyp-24) from mouse kidney: its inducibility by vitamin D-3.

    Biochimica et biophysica acta·1995
    Same author

    Evidence for the lack of hepatic N-acetyltransferase in suncus (Suncus murinus).

    Biochemical pharmacology·1995

    Area of Science:

    • Hepatology
    • Pharmacology
    • Immunology

    Background:

    • Hypertension is a common condition often managed with medications like hydralazine.
    • Drug-induced liver injury (DILI) is a significant concern in clinical practice.
    • Hydralazine, a vasodilator, has been associated with various adverse effects.

    Observation:

    • Three patients presented with hepatic injury at different time points (2 months, 10 months, 2 years) after initiating hydralazine therapy.
    • Clinical presentation included biochemical abnormalities and liver biopsy findings of centrilobular necrosis.
    • One patient with impaired liver synthetic function showed low Complement 3 and Complement 4 levels.

    Findings:

    • Discontinuation of hydralazine therapy resulted in clinical and biochemical recovery in all affected patients.

    Related Experiment Videos

  • Liver biopsies consistently revealed centrilobular necrosis, indicative of drug-induced hepatocellular damage.
  • Low complement levels correlated with poor liver synthetic function, suggesting an immune-mediated component.

    • Implications:

    • Hydralazine should be considered a potential cause of drug-induced liver injury.
    • Monitoring liver function is crucial for patients on long-term hydralazine therapy.
    • Abnormalities in hydralazine metabolism may underlie the pathogenesis of hydralazine-induced liver injury.